Michael Gibson, CEO of Baim Institute for Clinical Research, shared on X:
“EPIC17-VERONICA trial: Platelet reactivity testing to guide P2Y12 inhibitor de-escalation showed a neutral effect on the primary endpoint of net adverse clinical events at 12-month follow-up in ACS patients with very low platelet reactivity, demonstrating no significant reduction in events compared with continuation of potent P2Y12 inhibitors.”
Title: Platelet Reactivity Testing to Guide P2Y12 Inhibitor De-Escalation After Acute Coronary Syndrome: The EPIC17-VERONICA Randomized Clinical Trial
Author: Iñigo Lozano on behalf of the EPIC17-VERONICA investigators
You can also read:
